PGEN stock forecast, quote, news & analysis
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms... Show more
Why Precigen (PGEN) Stock Is Up +32.5% in the Last 30 Days
Key Takeaways
- Precigen shares advanced roughly 32.5% over the last 30 days, from a closing price of $5.17 on July 13, 2026, to $6.85 on August 12, 2026.
- The move was driven primarily by second-quarter 2026 results: total revenue of about $55 million, PAPZIMEOS revenue of $53.1 million, and net income of $20.1 million, or $0.05 per diluted share.
- Over the trailing quarter, the stock has risen approximately 65% from mid-May, reflecting accelerating commercial adoption of PAPZIMEOS and FDA-granted market exclusivity.
- Key risks include single-product concentration, expected gross-margin normalization, a modest cash balance, and insider selling.
Precigen (PGEN) Company Overview and Market Position
Precigen, Inc. is a commercial-stage biopharmaceutical company headquartered in Germantown, Maryland. The company develops precision medicines using its AdenoVerse immunotherapy platform, a library of proprietary adenovectors for gene delivery, alongside its UltraCAR-T cell therapy platform and UltraPorator manufacturing technology. Precigen was formerly known as Intrexon Corporation and adopted the Precigen name in February 2020.
Its lead commercial product, PAPZIMEOS (zopapogene imadenovec-drba, formerly PRGN-2012), is the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by chronic HPV 6 or HPV 11 infection. The therapy is delivered as four subcutaneous injections over 12 weeks and received full FDA approval in August 2025. The pipeline includes PRGN-2009 in Phase 2 development for HPV-related cancers. With a market capitalization of roughly $2.45 billion and about 358 million shares outstanding, Precigen is closely followed by biotech and small-cap investors for its commercial launch trajectory.
Precigen (PGEN) Stock Price Performance: Last 30 Days vs. Quarter
PGEN rose from $5.17 at the July 13, 2026 close to $6.85 at the August 12, 2026 close, a gain of approximately 32.5%. The stock touched a 52-week high around $7.32 in early August before settling back near $6.85, reflecting strong momentum alongside some post-earnings profit-taking.
The broader quarterly trend has been even more pronounced. From a closing price of $4.15 on May 13, 2026, shares have climbed about 65% through August 12. Measured from the post-first-quarter-earnings close of $4.60 on May 14, the advance is roughly 49%. The stock also nearly doubled from its early-June closing low of $3.57, underscoring a multi-month shift from caution about cash runway toward optimism about commercial execution.
What Drove PGEN Stock Price in the Last 30 Days
The principal catalyst was Precigen's second-quarter 2026 report, released after the market close on August 4. Total revenue reached approximately $55 million, well above consensus estimates near $28 million. PAPZIMEOS generated $53.1 million in net revenue, up from $21.6 million in the first quarter—sequential growth of more than 145%—and Precigen posted net income of $20.1 million, or $0.05 per diluted share, versus analyst expectations for a small loss.
Several commercial metrics reinforced the earnings beat. Management reported more than 500 patients registered through the PAPZIMEOS SUPPORT hub, over 200 patients treated with at least one dose, and payer coverage of approximately 315 million U.S. covered lives. The permanent J-code effective April 1, 2026 has helped institutional reimbursement, while FDA-granted seven-year market exclusivity protects the product through August 2032. Durability data showing 83% of patients in ongoing complete response beyond three years also supported the launch narrative.
Analyst response added fuel. H.C. Wainwright raised its price target to $18 with a Buy rating following the results, and consensus price targets sit around $14.50. The stock gapped higher after the report and closed up 5.5% on August 5. Offsetting factors included a relatively modest cash-and-investments balance of $38.7 million, reliance on $71.9 million in trade receivables to fund operations, expectations that gross margin will normalize from 95% toward the high-80s to low-90s range, and disclosed insider selling under pre-arranged plans.
What Drove PGEN Stock Performance Over the Last Quarter
The trailing-quarter move reflects a larger transition in how investors view Precigen. In May, first-quarter results showed PAPZIMEOS generating $21.6 million in its first full commercial quarter, with a sharply narrower net loss and management reiterating a path to cash-flow breakeven by the end of 2026. Analyst price targets moved higher, including increases from H.C. Wainwright and Citizens JMP.
In June, FDA orphan-drug exclusivity for PAPZIMEOS defined a clearer competitive runway for the adult RRP market, and the stock began recovering from its early-June trough. The August earnings release then converted launch promise into demonstrated profitability, cementing the quarter's upward trend. The broader narrative has shifted from a pre-commercial biotech with cash concerns to an early commercial-stage company with accelerating product revenue—though still highly dependent on a single product.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a broader universe of hundreds of bots that trade thousands of tickers. Rather than listing every available bot, the section surfaces top-performing and most relevant strategies, giving traders a focused view of current market activity. The bots vary by strategy, holding period, risk profile, and performance metrics, so the page is designed to help users identify approaches that may align with their own trading style. Investors monitoring stocks like Precigen can explore these tools as part of a broader research process. Visit Trending AI Robots to review the latest curated strategies.
PGEN Stock Forecast Drivers: What Investors Should Watch Next
- PAPZIMEOS demand: Third-quarter revenue, patient onboarding, account activation, and commentary on whether launch growth remains on track toward management's cash-flow breakeven target for the end of 2026.
- Margin and cost trends: Gross margin normalization toward the high-80s to low-90s range and expected increases in research and development spending.
- Pipeline catalysts: Updated Phase 2 data for PRGN-2009 in HPV-related head and neck and cervical cancers, planned pediatric PAPZIMEOS trial initiation, and progress on the European marketing application.
- Balance-sheet execution: Collection of trade receivables and whether operating cash flow inflects as commercial revenue scales.
- Market context: Small-cap biotechnology sentiment, sector rotation, and broader macroeconomic conditions that can amplify volatility in early commercial-stage biotech names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PGEN's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for PGEN moved out of overbought territory on August 11, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where PGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on August 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PGEN broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where PGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (50.000) is normal, around the industry mean (20.443). P/E Ratio (0.000) is within average values for comparable stocks, (24.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.844). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (26.385) is also within normal values, averaging (438.852).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology